ADARx Pharmaceuticals
PrivateLast Round
Strategic
May 14, 2025
Total Funding Raised
$331.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ADARx Pharmaceuticals is a biotechnology company that develops innovative therapeutics using a proprietary RNA targeting platform and advanced delivery technologies to treat genetic, cardiovascular, and central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ADARx Pharmaceuticals Comparables
Compare ADARx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanegene Bio | 83% | |
| Arrowhead Pharmaceuticals | 81% | |
| Silence Therapeutics plc | 78% |
ADARx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | May 14, 2025 | ||||
| Series C | Aug 9, 2023 | ||||
| Series B Extension | Jan 20, 2023 | ||||
| Series B | Sep 8, 2021 | ||||
| Series A | Nov 1, 2020 |
Key People
Founding team and executive leadership
ADARx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C |
| Sirona Capital | Series B, Series B Extension |
| Bain Capital Life Sciences | Series C |
| TCG Crossover | Series C |
| Cormorant Asset Management | Series C |
| OrbiMed | Series B Extension, Series C, Series A, Series B |
| Commodore Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 55% MoM.
- Mar 24, 2026
Ryan Fisk appointed as Chief Financial Officer and Chief Business Officer.
ADARx Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ADARx Pharmaceuticals's valuation, stock price, and market status.
Is ADARx Pharmaceuticals a public or private company?
ADARx Pharmaceuticals is a private company.
What is the current stock price of ADARx Pharmaceuticals?
ADARx Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is ADARx Pharmaceuticals worth (valuation)?
Valuation information for ADARx Pharmaceuticals is not publicly available.
Can I buy ADARx Pharmaceuticals stock?
ADARx Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ADARx Pharmaceuticals's last funding round?
ADARx Pharmaceuticals's most recent funding round was Corporate Funding on May 14, 2025.
Who are the main investors in ADARx Pharmaceuticals?
Key investors in ADARx Pharmaceuticals include Bain Capital Life Sciences, TCG Crossover, OrbiMed, HBM Healthcare Investments, Lilly Asia Ventures.
Will ADARx Pharmaceuticals IPO soon?
No public IPO plans have been announced for ADARx Pharmaceuticals.
How can I track ADARx Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ADARx Pharmaceuticals's secondary market activity and sign up for updates.